Systemic treatment decisions in older patients with early invasive breast cancer: Evidence and strategies
Ageing and Cancer Research & Treatment · 2025
DOI: 10.70401/acrt.2025.0001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ageing and Cancer Research & Treatment, 2025. Verfasst von Julia N. Wolbink und 3 weiteren Autor:innen. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The treatment of early invasive breast cancer in older patients poses unique challenges due to the distinct biological, clinical, and psychosocial complexities associated with aging. As the population of breast cancer patients aged 70 years and older continues to grow, their persistent underrepresentation in clinical trials remains a major obstacle to evidence-based treatment decision-making. To support the development of a more effective, personalized, and patient-centered approach to systemic therapy, this review outlines the biological features of breast cancer in older women, synthesizes current evidence on neoadjuvant and adjuvant systemic therapies, and discusses strategies for individualized treatment decision-making. Key recommendations include the use of hormonal therapy as the standard of care for hormone receptor positive breast cancer, neoadjuvant therapy primarily when tumor downstaging is desired, and chemotherapy or anti-human epidermal growth factor receptor 2 therapy for relatively fit older patients with high-risk subtypes. Additionally, bisphosphonates may help preserve bone health and reduce recurrence risk. Novel targeted therapies such as cyclin-dependent kinase 4 and 6 inhibitors and immune checkpoint inhibitors show promise, though further studies are needed to confirm their safety and efficacy in older populations. Comprehensive geriatric assessments are essential for identifying patient frailty and vulnerabilities, while predictive tools such as the Cancer and Aging Research Group Breast Cancer model can help assess toxicity risk. In this population, competing risks of non-cancer-related mortality may reduce the absolute benefit of systemic treatment. For patients with elevated risks of other-cause mortality, the potential survival benefit of cancer therapy may be negligible. Predictive models that account for competing mortality, such as the PORTRET tool, can facilitate personalized and shared decision-making.
Zitieren
APA
Wolbink, J. N., Bodegom-Vos, L. V., Blok, E. J., & Portielje, J. E. A. (2025). Systemic treatment decisions in older patients with early invasive breast cancer: Evidence and strategies. Ageing and Cancer Research & Treatment. https://doi.org/10.70401/acrt.2025.0001
Vancouver
Wolbink JN, Bodegom-Vos LV, Blok EJ, Portielje JEA. Systemic treatment decisions in older patients with early invasive breast cancer: Evidence and strategies. Ageing and Cancer Research & Treatment. 2025. doi:10.70401/acrt.2025.0001
BibTeX
@article{Wolbink2025,
author = {Wolbink, Julia N. and Bodegom-Vos, Leti van and Blok, Erik J. and Portielje, Johanneke E. A.},
title = {Systemic treatment decisions in older patients with early invasive breast cancer: Evidence and strategies},
journal = {Ageing and Cancer Research & Treatment},
year = {2025},
doi = {10.70401/acrt.2025.0001}
}
EUVIMED